RT Journal Article
SR Electronic
T1 Pentraxin 3: A Novel Biomarker for Predicting Progression from Prostatic Inflammation to Prostate Cancer
JF Cancer Research
JO Cancer Res
FD American Association for Cancer Research
SP 4230
OP 4238
DO 10.1158/0008-5472.CAN-14-0369
VO 74
IS 16
A1 Stallone, Giovanni
A1 Cormio, Luigi
A1 Netti, Giuseppe Stefano
A1 Infante, Barbara
A1 Selvaggio, Oscar
A1 Fino, Giuseppe Di
A1 Ranieri, Elena
A1 Bruno, Francesca
A1 Prattichizzo, Clelia
A1 Sanguedolce, Francesca
A1 Tortorella, Simona
A1 Bufo, Pantaleo
A1 Grandaliano, Giuseppe
A1 Carrieri, Giuseppe
YR 2014
UL http://cancerres.aacrjournals.org/content/74/16/4230.abstract
AB Pentraxin-3 (PTX3) is a member of the pentraxin family of innate immune regulators, which includes C-reactive protein (CRP). PTX3 has been implicated in angiogenesis, proliferation, and immune escape in cancer. In the present study, we evaluated PTX3 tissue expression and serum concentration as a biomarker to discriminate prostatic inflammation and benign prostatic hyperplasia (BPH) from prostate cancer, and to determine whether PTX3 status may predict progression from BPH to prostate cancer. We analyzed 40 patients with biopsy-proven BPH who underwent a second prostate biopsy 12 to 36 months later when they were diagnosed with prostate cancer or inflammation/BPH (n = 20 patients each group). Furthermore, we evaluated PTX3 serum concentrations in an independent set of patients with biopsy-proven inflammation/BPH (n = 61) and prostate cancer (n = 56). We found reduced PTX3 tissue expression in patients with prostatic inflammation/BPH compared with patients who developed prostate cancer. In the latter group, there was an increase in PTX3 tissue expression between the first and second prostate biopsy. PTX3 serum levels were also higher in patients with prostate cancer than in patients with inflammation/BPH. In contrast, there was no difference in serum PSA or CRP levels in these two groups. ROC curve analysis confirmed the reliability of PTX3 serum levels in predicting prostate cancer development, identifying a cutoff value of 3.25 ng/mL with a sensitivity and a specificity of 89.3% and 88.5%, respectively. In summary, our results encourage further evaluation of PTX3 as a tissue biopsy and blood-borne biomarker to discriminate BPH from prostate cancer. Cancer Res; 74(16); 4230–8. ©2014 AACR.